Literature DB >> 4600047

Suppression of human growth hormone secretion by melatonin and cyproheptadine.

G A Smythe, L Lazarus.   

Abstract

Pituitary growth hormone (GH) release in the rat is stimulated via serotoninergic pathways and can be inhibited by treatment with compounds that act as serotonin antagonists, such as cyproheptadine or the pineal gland hormone, melatonin. To investigate a possible role for serotonin in the control of human GH release, the effects of cyproheptadine and melatonin administration on the GH responses of normal male subjects were examined. The oral administration of cyproheptadine (8-12 mg daily for 5 days) to normal subjects reduced their GH responses to both insulin-induced hypoglycemia and physical exercise to a highly significant extent. Similarly, the mean GH responses of 10 subjects to insulin-induced hypoglycemia were significantly reduced after the prior oral administration of melatonin (1 g). The data presented show that serotonin antagonism has a similar effect on GH secretion in man to that observed in the rat and provides further evidence for serotoninergic, and possibly pineal, involvement in the control of human GH secretion.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4600047      PMCID: PMC301530          DOI: 10.1172/JCI107732

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Absent sleep peak of growth hormone release in blind subjects: ccorrelation with sleep EEG stages.

Authors:  D T Krieger; S Glick
Journal:  J Clin Endocrinol Metab       Date:  1971-11       Impact factor: 5.958

Review 2.  Correlations between protein and serotonin synthesis during various activities of the central nervous system (slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressiveness, and pharmacological action of sodium gamma-hydroxybutyrate).

Authors:  H Laborit
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-01

3.  Adrenergic and serotoninergic control of growth hormone secretion in adult male rats.

Authors:  R Collu; F Fraschini; P Visconti; L Martini
Journal:  Endocrinology       Date:  1972-05       Impact factor: 4.736

4.  The effects of 5-hydroxytryptamine antagonists on spinal neuronal activity.

Authors:  N R Banna; E G Anderson
Journal:  J Pharmacol Exp Ther       Date:  1968-08       Impact factor: 4.030

5.  Radioimmunoassay of human growth hormone.

Authors:  G M Molinatti; F Massara; E Strumia; F Pennisi; G A Scassellati; L Vancheri
Journal:  J Nucl Biol Med       Date:  1969 Jan-Jun

6.  Growth and new growth: environmental carcinogens in the process of human ontogeny.

Authors:  K W Starr
Journal:  Prog Clin Cancer       Date:  1970

7.  Stimulation of human-growth-hormone secretion by L-dopa.

Authors:  A E Boyd; H E Lebovitz; J B Pfeiffer
Journal:  N Engl J Med       Date:  1970-12-24       Impact factor: 91.245

8.  Serotonin, 5-hydroxyindoleacetic acid (5-HIAA), and monoamide oxidase in the bovine median eminence and pituitary gland.

Authors:  R S Piezzi; F Larin; R J Wurtman
Journal:  Endocrinology       Date:  1970-06       Impact factor: 4.736

9.  Adrenergic receptor control mechanism for growth hormone secretion.

Authors:  W G Blackard; S A Heidingsfelder
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

10.  Growth hormone secretion during sleep.

Authors:  Y Takahashi; D M Kipnis; W H Daughaday
Journal:  J Clin Invest       Date:  1968-09       Impact factor: 14.808

View more
  18 in total

Review 1.  Light, blindness and endocrine secretions.

Authors:  A Bellastella; G Amato; A Bizzaro; C Carella; T Criscuolo; S Iorio; V I Muccitelli; G Pisano; A A Sinisi; A De Bellis
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

2.  The pineal gland-opioid system relation: melatonin-naloxone interactions in regulating GH and LH releases in man.

Authors:  D Esposti; P Lissoni; R Mauri; F Rovelli; L Orsenigo; S Pescia; G Vegetti; G Esposti; F Fraschini
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

Review 3.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

4.  Twenty-four hour melatonin pattern in acromegaly: effect of acute octreotide administration.

Authors:  A A Sinisi; D Pasquali; A D'Apuzzo; D Esposito; T Venditto; T Criscuolo; A De Bellis; A Bellastella
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

5.  Stimulation and suppression of somatomedin activity by serotonin and melatonin.

Authors:  G A Smythe; M C Stuart; L Lazarus
Journal:  Experientia       Date:  1974-11-15

6.  Hypothalamic control of GH secretion: pathophysiology and clinical implications.

Authors:  H J Quabbe
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

7.  Circadian profile of serum melatonin in patients with Cushing's syndrome or acromegaly.

Authors:  M Terzolo; A Piovesan; A Alì; A Codegone; A Pia; G Reimondo; M Torta; P Paccotti; G Borretta; A Angeli
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

8.  Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.

Authors:  J Rotrosen; B M Angrist; S Gershon; E J Sachar; F S Halpern
Journal:  Psychopharmacology (Berl)       Date:  1976-12-21       Impact factor: 4.530

9.  Improved oral glucose tolerance following antiserotonin treatment in patients with chemical diabetes.

Authors:  C Ferrari; C Barbieri; R Caldara; V Magnoni; G P Testori; M Romussi
Journal:  Eur J Clin Pharmacol       Date:  1979-07       Impact factor: 2.953

10.  The inhibiting effect of atropine on growth hormone release during exercise.

Authors:  J D Few; C T Davies
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.